刺痛激动剂SMA-2通过改善瘤微环境来抑制清细胞细胞癌
Wei Wang1, Fengqing Zhang2, Yan Hu3
1Department of Urology, Tianjin First Central Hospital, NO.24 Fukang Road, Nankai District, Tianjin, 300192, People's Republic of China.
Molecular and cellular biochemistry
|April 9, 2024
概括
一种新型的STING激动剂,MSA-2,通过增强免疫细胞活性和延长小鼠的存活时间,有效地对抗清细胞细胞癌 (ccRCC). 这种免疫疗法对治疗这种侵袭性癌非常有前途.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 清细胞细胞癌 (ccRCC) 是最常见和最致命的癌亚型.
- 患有ccRCC的患者经常面临不良预后和有限的生存率.
- 对于管理ccRCC进展的新型治疗策略至关重要.
研究的目的:
- 在ccRCC的临床前模型中研究STING激动剂MSA-2的治疗潜力.
- 阐明MSA-2影响瘤生长和瘤微环境 (TME) 的机制.
- 评估MSA-2作为ccRCC的潜在辅助免疫疗法.
主要方法:
- 向携带ccRCC瘤的小鼠给予MSA-2.
- 评估瘤进展,生存率和细胞因子分泌.
- 对CD8+T细胞贩运和透到TME的分析.
- 在ccRCC TME中,化学激素环境的表征.
主要成果:
- 在ccRCC小鼠模型中,MSA-2显著抑制瘤进展和延长存活时间.
- MSA-2治疗导致细胞因子的分泌量增加.
- 这种STING激动剂促进了CD8+T细胞的贩运和透.
- MSA-2通过产生特定的化基因环境来调节免疫抑制的TME.
结论:
- MSA-2对ccRCC具有强大的抗瘤活性.
- MSA-2通过促进T细胞透和细胞因子产生来增强抗瘤免疫力.
- 在ccRCC治疗中,MSA-2是辅助免疫疗法的有希望的候选人.
更多相关视频
09:17Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy
Published on: September 16, 2019
6.8K
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
13.6K
相关概念视频
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Tumor Immunotherapy
522
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
522
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
